Skip to main navigation
Skip to search
Skip to main content
Universidad de los Andes Home
English
Español
Search content at Universidad de los Andes
Home
Profiles
Research units
Research output
Projects
Press/Media
Activities
Equipment
Student theses
Prizes
Courses
Impacts
Angiogenesis inhibitors in early development for gastric cancer
Mauricio P. Pinto
, Gareth I. Owen
, Ignacio Retamal
, Marcelo Garrido
*
*
Corresponding author for this work
Research output
:
Contribution to journal
›
Review article
›
peer-review
34
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Angiogenesis inhibitors in early development for gastric cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Angiogenesis
40%
Angiogenesis Inhibitors
100%
Antiangiogenic
20%
Antiangiogenic Activity
20%
Antiangiogenic Properties
20%
Area Cover
20%
Clinical Setting
20%
Clinical Trials
20%
Early Development
100%
Expert Opinion
20%
Gastric Cancer
100%
Growth Factor Pathway
20%
Immune Checkpoint Inhibitors
40%
Immunomodulatory Drugs (IMiDs)
20%
Mammalian Target of Rapamycin Pathway
20%
Molecular Subtype Classification
20%
Monoclonal Antibody
20%
Nanotechnology
20%
New Blood Vessel
20%
Precision Medicine
20%
Ramucirumab
60%
Second-line Therapy
20%
Targeted Agents
20%
Therapeutic Potential
20%
Therapeutic Target
20%
Tumor Growth
20%
Tumor Progression
20%
Tyrosine Kinase Inhibitor
20%
Vascular Endothelial Growth Factor
20%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
20%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
100%
Angiogenesis Inhibitor
100%
Antiangiogenic
60%
Clinical Study
20%
Clinical Trial
20%
Immune Checkpoint Inhibitor
40%
Immunotherapy
20%
Mammalian Target of Rapamycin
20%
Monoclonal Antibody
20%
Protein Tyrosine Kinase Inhibitor
20%
Ramucirumab
60%
Tumor Growth
40%
Vasculotropin
20%